Literature DB >> 16291812

B lymphocyte maturation in Wegener's granulomatosis: a comparative analysis of VH genes from endonasal lesions.

J Voswinkel1, A Mueller, J A Kraemer, P Lamprecht, K Herlyn, K Holl-Ulrich, A C Feller, S Pitann, A Gause, W L Gross.   

Abstract

BACKGROUND: Anti-neutrophil cytoplasmic antibodies (ANCA) directed against proteinase 3 (PR3) are highly specific for Wegener's granulomatosis (WG). Evidence for a pivotal role of PR3-ANCA in the induction of vasculitis has been demonstrated. B cell clusters have been observed within endonasal biopsy specimens.
OBJECTIVES: To determine whether B cell selection and maturation take place in granulomatous lesions of WG.
METHODS: Granulomatous lesions and the immunoglobulin (VH) gene repertoire from nasal tissue of six WG patients-two active and two smouldering localised WG (ANCA negative, restricted to respiratory tract), plus one active and one smouldering PR3-ANCA positive generalised WG-were characterised by immunohistochemistry, polymerase chain reaction, cloning, DNA sequencing and database comparison.
RESULTS: B lymphocyte-rich, follicle-like areas were observed proximal to PR3 positive cells and plasma cells in granulomatous lesions; 184 VH genes from these granulomatous lesions were compared with 84 VH genes from peripheral blood of a healthy donor. The mutational pattern of VH genes from active WG resembled memory B cells. Structural homologies of VH genes from granulomatous lesions to PR3-ANCA encoding genes were detected. Significantly more genes (55%, 45%, and 53%, respectively) from active WG compared with the healthy repertoire carried mutations to negatively charged amino acids within the binding site coding regions, favouring affinity to the positively charged PR3.
CONCLUSIONS: Selection and affinity maturation of potentially PR3-ANCA producing autoreactive B cells may start in granulomatous lesions, thereby contributing to disease progression from ANCA negative localised to PR3-ANCA positive generalised WG.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16291812      PMCID: PMC1798221          DOI: 10.1136/ard.2005.044909

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  30 in total

1.  Analysis of heavy and light chain pairings indicates that receptor editing shapes the human antibody repertoire.

Authors:  R M de Wildt; R M Hoet; W J van Venrooij; I M Tomlinson; G Winter
Journal:  J Mol Biol       Date:  1999-01-22       Impact factor: 5.469

Review 2.  Somatic hypermutation in normal and transformed human B cells.

Authors:  U Klein; T Goossens; M Fischer; H Kanzler; A Braeuninger; K Rajewsky; R Küppers
Journal:  Immunol Rev       Date:  1998-04       Impact factor: 12.988

3.  Evidence for a selected humoral immune response encoded by VH4 family genes in the synovial membrane of a patient with rheumatoid arthritis (RA).

Authors:  J Voswinkel; L Trümper; G Carbon; T Hopf; M Pfreundschuh; A Gause
Journal:  Clin Exp Immunol       Date:  1996-10       Impact factor: 4.330

4.  Structural analysis of human antibodies to proteinase 3 from patients with Wegener granulomatosis.

Authors:  J Sibilia; K Benlagha; P Vanhille; P Ronco; J C Brouet; X Mariette
Journal:  J Immunol       Date:  1997-07-15       Impact factor: 5.422

5.  Analysis of the heavy chain repertoire of human peripheral B cells using single-cell polymerase chain reaction.

Authors:  H P Brezinschek; R I Brezinschek; P E Lipsky
Journal:  J Immunol       Date:  1995-07-01       Impact factor: 5.422

6.  Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization.

Authors:  E C Hagen; M R Daha; J Hermans; K Andrassy; E Csernok; G Gaskin; P Lesavre; J Lüdemann; N Rasmussen; R A Sinico; A Wiik; F J van der Woude
Journal:  Kidney Int       Date:  1998-03       Impact factor: 10.612

7.  Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Karina A Keogh; Mark E Wylam; John H Stone; Ulrich Specks
Journal:  Arthritis Rheum       Date:  2005-01

8.  Differential binding avidities of human IgM for staphylococcal protein A derive from specific germ-line VH3 gene usage.

Authors:  M Hakoda; N Kamatani; S Hayashimoto-Kurumada; G J Silverman; H Yamanaka; C Terai; S Kashiwazaki
Journal:  J Immunol       Date:  1996-10-01       Impact factor: 5.422

9.  Epitopes on proteinase-3 recognized by antibodies from patients with Wegener's granulomatosis.

Authors:  R C Williams; R Staud; C C Malone; J Payabyab; L Byres; D Underwood
Journal:  J Immunol       Date:  1994-05-01       Impact factor: 5.422

10.  Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group.

Authors:  C A Stegeman; J W Tervaert; P E de Jong; C G Kallenberg
Journal:  N Engl J Med       Date:  1996-07-04       Impact factor: 91.245

View more
  42 in total

Review 1.  ANCA-associated vasculitides--advances in pathogenesis and treatment.

Authors:  Min Chen; Cees G M Kallenberg
Journal:  Nat Rev Rheumatol       Date:  2010-10-05       Impact factor: 20.543

Review 2.  ANCA-associated vasculitides-lessons from the adult literature.

Authors:  Joannis Vamvakopoulos; Caroline O Savage; Lorraine Harper
Journal:  Pediatr Nephrol       Date:  2010-04-01       Impact factor: 3.714

3.  Successful remission induction with a combination therapy of rituximab, cyclophosphamide, and steroids in a patient with refractory optic neuritis in Wegener's granulomatosis.

Authors:  Cord Huchzermeyer; Christian Mardin; Leonard Holbach; Jochen Zwerina; Georg Schett; Jürgen Rech
Journal:  Clin Rheumatol       Date:  2010-09-23       Impact factor: 2.980

Review 4.  Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis?

Authors:  O Flossmann; R B Jones; D R W Jayne; R A Luqmani
Journal:  Ann Rheum Dis       Date:  2006-07       Impact factor: 19.103

5.  Analysis of Wegener's granulomatosis responses to rituximab: current evidence and therapeutic prospects.

Authors:  Achille Aouba; Christian Pagnoux; Boris Bienvenu; Alfred Mahr; Loïc Guillevin
Journal:  Clin Rev Allergy Immunol       Date:  2007-09-12       Impact factor: 8.667

Review 6.  Wegener's granulomatosis: the current view.

Authors:  Frank Moosig; Peter Lamprecht; Wolfgang L Gross
Journal:  Clin Rev Allergy Immunol       Date:  2008-10       Impact factor: 8.667

Review 7.  Targeted biologic approaches to the treatment of systemic vasculitis.

Authors:  Andreea Coca; Jennifer H Anolik
Journal:  Clin Rev Allergy Immunol       Date:  2008-10       Impact factor: 8.667

Review 8.  [Wegener's granulomatosis and microscopic polyangiitis].

Authors:  K de Groot; E Reinhold-Keller
Journal:  Z Rheumatol       Date:  2009-02       Impact factor: 1.372

9.  Single cell analysis of B lymphocytes from Wegener's granulomatosis: B cell receptors display affinity maturation within the granulomatous lesions.

Authors:  J Voswinkel; G Assmann; G Held; S Pitann; W L Gross; K Holl-Ulrich; K Herlyn; A Mueller
Journal:  Clin Exp Immunol       Date:  2008-09-23       Impact factor: 4.330

Review 10.  T cells in ANCA-associated vasculitis: what can we learn from lesional versus circulating T cells?

Authors:  Benjamin Wilde; Marielle Thewissen; Jan Damoiseaux; Pieter van Paassen; Oliver Witzke; Jan Willem Cohen Tervaert
Journal:  Arthritis Res Ther       Date:  2010-02-24       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.